Research graph
References from Toward Tumor-Conditional Release of Histone Deacetylase Inhibitors from Nongenotoxic Drug Conjugates. Local targets link to admitted publications; unresolved targets remain external evidence.
Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders
10.1038/nrd4360 · 2014 · External reference
Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
10.1111/j.1749-6632.2003.tb05964.x · 2003 · External reference
Histone Deacetylases and Cancer
10.1038/sj.onc.1210610 · 2007 · External reference
Anticancer Activities of Histone Deacetylase Inhibitors
10.1038/nrd2133 · 2006 · External reference
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
10.1002/cmdc.201500486 · 2016 · External reference
Combination Therapy with Histone Deacetylase Inhibitors (Hdaci) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of Hdaci
10.3389/fonc.2018.00092 · 2018 · External reference
Panobinostat Approved for Multiple Myeloma
10.1158/2159-8290.cd-nb2015-040 · 2015 · External reference
HDAC Inhibitors Still Need a Home Run, despite Recent Approval
10.1038/nrd4583 · 2015 · External reference
Approvals in 2021: Dangling Accelerated Approvals, Drug Dosing, New Approvals and Beyond
10.1038/s41571-022-00605-5 · 2022 · External reference
Next-Generation of Selective Histone Deacetylase Inhibitors
10.1039/c9ra02985k · 2019 · External reference
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
10.1021/acs.jmedchem.3c00226 · 2023 · External reference
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential
10.1021/acs.jmedchem.5c01677 · 2025 · External reference
A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes
10.1021/acs.accounts.7b00242 · 2017 · External reference
Hypoxia-Activated pro-Drugs of the KDAC Inhibitor Vorinostat (SAHA)
10.1016/j.tet.2020.131170 · 2020 · External reference
Development and Pre-Clinical Testing of a Novel Hypoxia-Activated KDAC Inhibitor
10.1016/j.chembiol.2021.04.004 · 2021 · External reference
Metronidazole Induces Genotoxicity, Hepato- and Nephrotoxicity by Triggering DNA Fragmentation in Swiss Albino Mice (Balb/C)
10.1038/s41598-025-12230-0 · 2025 · External reference
Efficient and Stereocontrolled Synthesis of 1,2,4-Trioxolanes Useful for Ferrous Iron-Dependent Drug Delivery
10.1021/ol5028392 · 2014 · External reference
Drug Delivery to the Malaria Parasite Using an Arterolane-like Scaffold
10.1002/cmdc.201402362 · 2015 · External reference
A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models
10.1021/acs.jmedchem.6b01470 · 2016 · External reference
10.2139/ssrn.3581366
10.2139/ssrn.3581366 · External reference
Targeting Mobilization of Ferrous Iron in Pseudomonas Aeruginosa Infection with an Iron(II)-Caged LpxC Inhibitor
10.1021/acsinfecdis.9b00057 · 2019 · External reference
Unresolved reference
External reference
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice
10.1158/1535-7163.mct-18-0329 · 2018 · External reference
Drug Delivery to the Malaria Parasite Using an Arterolane-like Scaffold
10.1002/cmdc.201402362 · ExternalCitation · doi-reference
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
10.1002/cmdc.201500486 · ExternalCitation · doi-reference
Development and Pre-Clinical Testing of a Novel Hypoxia-Activated KDAC Inhibitor
10.1016/j.chembiol.2021.04.004 · ExternalCitation · doi-reference
Hypoxia-Activated pro-Drugs of the KDAC Inhibitor Vorinostat (SAHA)
10.1016/j.tet.2020.131170 · ExternalCitation · doi-reference
A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes
10.1021/acs.accounts.7b00242 · ExternalCitation · doi-reference
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
10.1021/acs.jmedchem.3c00226 · ExternalCitation · doi-reference
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential
10.1021/acs.jmedchem.5c01677 · ExternalCitation · doi-reference
A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models
10.1021/acs.jmedchem.6b01470 · ExternalCitation · doi-reference
Targeting Mobilization of Ferrous Iron in Pseudomonas Aeruginosa Infection with an Iron(II)-Caged LpxC Inhibitor
10.1021/acsinfecdis.9b00057 · ExternalCitation · doi-reference
Efficient and Stereocontrolled Synthesis of 1,2,4-Trioxolanes Useful for Ferrous Iron-Dependent Drug Delivery
10.1021/ol5028392 · ExternalCitation · doi-reference
Anticancer Activities of Histone Deacetylase Inhibitors
10.1038/nrd2133 · ExternalCitation · doi-reference
Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders
10.1038/nrd4360 · ExternalCitation · doi-reference
HDAC Inhibitors Still Need a Home Run, despite Recent Approval
10.1038/nrd4583 · ExternalCitation · doi-reference
Approvals in 2021: Dangling Accelerated Approvals, Drug Dosing, New Approvals and Beyond
10.1038/s41571-022-00605-5 · ExternalCitation · doi-reference
Metronidazole Induces Genotoxicity, Hepato- and Nephrotoxicity by Triggering DNA Fragmentation in Swiss Albino Mice (Balb/C)
10.1038/s41598-025-12230-0 · ExternalCitation · doi-reference
Histone Deacetylases and Cancer
10.1038/sj.onc.1210610 · ExternalCitation · doi-reference
Next-Generation of Selective Histone Deacetylase Inhibitors
10.1039/c9ra02985k · ExternalCitation · doi-reference
Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
10.1111/j.1749-6632.2003.tb05964.x · ExternalCitation · doi-reference
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice
10.1158/1535-7163.mct-18-0329 · ExternalCitation · doi-reference
Panobinostat Approved for Multiple Myeloma
10.1158/2159-8290.cd-nb2015-040 · ExternalCitation · doi-reference
10.2139/ssrn.3581366
10.2139/ssrn.3581366 · ExternalCitation · doi-reference
Combination Therapy with Histone Deacetylase Inhibitors (Hdaci) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of Hdaci
10.3389/fonc.2018.00092 · ExternalCitation · doi-reference
